116 related articles for article (PubMed ID: 7530944)
1. Pharmacological treatment of benign prostatic hyperplasia with finasteride: a clinical review.
Ekman P
Arch Esp Urol; 1994 Nov; 47(9):883-7; discussion 887-8. PubMed ID: 7530944
[TBL] [Abstract][Full Text] [Related]
2. [Finasteride in the treatment of benign prostatic hypertrophy].
Ekman P
J Urol (Paris); 1993; 99(6):299-302. PubMed ID: 7516372
[TBL] [Abstract][Full Text] [Related]
3. Endocrine therapy for benign prostatic hyperplasia in the 90's.
Ekman P
J Urol (Paris); 1995; 101(1):22-5. PubMed ID: 7545721
[TBL] [Abstract][Full Text] [Related]
4. Maintenance of clinical efficacy with finasteride therapy for 24 months in patients with benign prostatic hyperplasia. The Finasteride Study Group.
Stoner E
Arch Intern Med; 1994 Jan; 154(1):83-8. PubMed ID: 7505563
[TBL] [Abstract][Full Text] [Related]
5. Finasteride in the treatment of benign prostatic hyperplasia.
Ekman P; Andersen JT; Wolf H
Acta Urol Belg; 1996 Mar; 64(1):IX-XII. PubMed ID: 8659328
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of benign prostatic hyperplasia with Proscar (finasteride). Results of a 10-year Scandinavian study].
Tveter KJ; Beisland HO; Andersen JT; Wolf H; Ekman P; Johansson JE; Kontturi M; Lehtonen T
Tidsskr Nor Laegeforen; 1996 Nov; 116(27):3226-30. PubMed ID: 9011975
[TBL] [Abstract][Full Text] [Related]
7. [New prospective therapy for benign prostatic hyperplasia with finasteride].
Miano L; Manieri C; Paradiso Galatioto G; Vicentini C
Riv Eur Sci Med Farmacol; 1993; 15(2):111-9. PubMed ID: 7513437
[TBL] [Abstract][Full Text] [Related]
8. 5alpha-reductase inhibitors/finasteride.
Stoner E
Prostate Suppl; 1996; 6():82-7. PubMed ID: 8630236
[TBL] [Abstract][Full Text] [Related]
9. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.
Naslund MJ; Miner M
Clin Ther; 2007 Jan; 29(1):17-25. PubMed ID: 17379044
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of benign prostatic hyperplasia with finasteride. Results after 7 years of follow-up].
Martínez Sarmiento M; Cuñat Albert E; López Alcina E; Pontones Moreno JL; Sanz Chinesta S; Jiménez Cruz JF
Actas Urol Esp; 1997 Feb; 21(2):105-10. PubMed ID: 9214205
[TBL] [Abstract][Full Text] [Related]
11. Clinical and biological characteristics of familial benign prostatic hyperplasia.
Sanda MG; Doehring CB; Binkowitz B; Beaty TH; Partin AW; Hale E; Stoner E; Walsh PC
J Urol; 1997 Mar; 157(3):876-9. PubMed ID: 9072590
[TBL] [Abstract][Full Text] [Related]
12. [Finanseride in symtomatic benign prostatic hyeprtrophy. A 2-year placebo-controlled study].
Andersen JT; Wolf H; Ekman P; Beisland HO; Johansson JE; Kontturi M; Lehtonen T; Tveter K
Ugeskr Laeger; 1996 Sep; 158(36):5030-5. PubMed ID: 8928243
[TBL] [Abstract][Full Text] [Related]
13. Finasteride in the treatment of patients with moderate symptoms of benign prostatic hyperplasia.
Magoha GA
East Afr Med J; 1998 May; 75(5):260-3. PubMed ID: 9746993
[TBL] [Abstract][Full Text] [Related]
14. Finasteride following balloon dilatation of the prostate. A double-blind, placebo-controlled, multicenter study.
Lukkarinen O; Lehtonen T; Talja M; Lundstedt S; Tiitinen J; Taari K
Ann Chir Gynaecol; 1999; 88(4):299-303. PubMed ID: 10661828
[TBL] [Abstract][Full Text] [Related]
15. One-year experience in the treatment of benign prostatic hyperplasia with finasteride. The MK-906 (Finasteride) Study Group.
J Androl; 1991; 12(6):372-5. PubMed ID: 1722792
[TBL] [Abstract][Full Text] [Related]
16. Effect of long-term administration of finasteride (MK-906), an inhibitor of 5 alpha-reductase, in patients with benign prostatic hyperplasia.
Yoshida O; Oishi K; Okada Y; Mizutani Y; Itokawa Y; Tomoyoshi T; Okada K; Komatz Y; Matsuda T; Takeuchi H
Hinyokika Kiyo; 1996 Apr; 42(4):323-31. PubMed ID: 8693970
[TBL] [Abstract][Full Text] [Related]
17. [Effect of dutasteride on reduction of plasma DHT following finasteride therapy in patients with benign prostatic hyperplasia].
Botto H; Lan O; Poulain JE; Comenducci A
Prog Urol; 2005 Dec; 15(6):1090-5. PubMed ID: 16429658
[TBL] [Abstract][Full Text] [Related]
18. [Medical treatment of benign prostatic hyperplasia. The efficacy of finasteride depends on prostatic volume].
Granados Loarca EA
Arch Esp Urol; 1999 Apr; 52(3):201-8. PubMed ID: 10371735
[TBL] [Abstract][Full Text] [Related]
19. [The effect of 5-alpha-reductase inhibitors on benign prostatic hyperplasia].
Djavan B; McConnell J
Wien Med Wochenschr; 1996; 146(8):165-8. PubMed ID: 8767401
[TBL] [Abstract][Full Text] [Related]
20. Clinical predictors in the use of finasteride for control of gross hematuria due to benign prostatic hyperplasia.
Kearney MC; Bingham J; Bergland R; Meade-D'Alisera P; Puchner PJ
J Urol; 2002 Jun; 167(6):2489-91. PubMed ID: 11992064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
